Paolo Tarantino: Recap of the first 40 years of ADC development – OncoDaily
Paolo Tarantino: Recap of the first 40 years of ADC development / AACR25, ADC development, antibody, cancer, Cancer Discovery, drug conjugates, fight against
Paolo Tarantino: Recap of the first 40 years of ADC development / AACR25, ADC development, antibody, cancer, Cancer Discovery, drug conjugates, fight against
Oncodaily – Oncology News, Insights, Stories
Vraj Rangrej: Voices in Lymphoma – Women Shaping Care / cancer, Catherine Thieblemont, lymphoma, Marginal Zone Lymphomas, Memorial Sloan Kettering Cancer
Explore the challenges of RAS inhibitor resistance in PDAC. Learn how KRAS mutations affect treatment outcomes.
Piet Ost: MDT vs ENRT and MDT for Nodal Oligorecurrent Prostate Cancer / Alexandros Papachristofilou, Alfonso Gomez-Iturriaga, Almudena Zapatero, Ana-Elena
Wafik S. El-Deiry highlights Paul Calabresi’s contributions and ongoing challenges in securing the NCI K12 Award.
Discover the impact of PD-1 immunotherapy on MMRd/MSI-H tumors. Learn about breakthrough results from AACR 2025.
Explore the transformative potential of Antibody-Drug Conjugates in targeted cancer treatments and their impact on precision medicine.
Explore the impact of Zongertinib HER2-Mutant NSCLC treatment with a 71% response rate in the latest Beamion LUNG-1 trial.
Yelak Biru: Rahul Banerjee on redefining ‘cure’ in myeloma / cancer, Myeloma, OncoDaily, Oncology, Rahul Banerjee, Yelak Biru
Myeloma Paper of the Day, May 1st, suggested by Robert Orlowski / Azeem Banatwala, cancer, Christopher Herrick, Elizabeth O’Donnell, Gregory Belsky,